Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
It is established that nebivolol delivers significant SBP and DBP lowering compared with placebo, whilst outperforming traditional beta-blockers in overall blood pressure normalisation, reinforces nebivolol as an optimal therapeutic choice for managing hypertension across diverse patient groups.
Abstract
Nebivolol functions as a third-generation, highly selective beta1-adrenoceptor antagonist distinguished by its nitric oxide-inducing vasodilatory capabilities.
The current network meta-analysis (NMA) was designed to appraise the clinical effectiveness and safety profile of nebivolol in contrast to placebo and alternative blood pressure-lowering therapies.
A comprehensive literature review was executed across primary databases, including Cochrane CENTRAL, Embase, and PubMed, up to June 2025. The analysis incorporated both randomised and non-randomised controlled trials that evaluated nebivolol against placebo, alternate beta-blockers, or other primary antihypertensive drugs. Following rigorous data extraction and bias risk evaluations, a frequentist NMA was performed via R software. The present findings highlight the comparative outcomes of nebivolol against placebo and other beta-blockers, expressing results as mean differences.
The systematic review and subsequent NMA comprised 108 individual studies. Administration of 5 mg nebivolol yielded substantial reductions in systolic blood pressure (SBP) of −9.95 mmHg (95% confidence interval [CI]: −15.88 to −4.02) and diastolic blood pressure (DBP) of −5.29 mmHg (95% CI: −7.33 to −3.26) relative to placebo. Subgroup assessments of individuals under 50 years of age showed sustained benefits, with SBP decreasing by −8.50 mmHg (95% CI: −16.99 to −0.01) and DBP by −7.06 mmHg (95% CI: −8.77 to −5.35) versus placebo. Relative to alternative beta-blockers, nebivolol demonstrated a superior probability of achieving target blood pressure (SBP <140 mmHg and DBP <90 mmHg) at doses of 2.5 mg (odds ratio [OR] = 4.14; 95% CI: 1.96–8.75) and 5 mg (OR = 1.15; 95% CI: 0.58–2.29). Additionally, nebivolol conferred a significant enhancement in erectile capability compared with metoprolol (an increase of 3.45 International Index of Erectile Function-5 points; 95% CI: 1.17–5.72). Safety evaluations confirmed that standard 5 mg dosing did not elevate adverse event rates compared with placebo (OR = 0.98; 95% CI: 0.77–1.26).
This comprehensive NMA establishes that nebivolol delivers significant SBP and DBP lowering compared with placebo, whilst outperforming traditional beta-blockers in overall blood pressure normalisation. Its proven efficacy in younger demographics, combined with a highly favourable impact on erectile function, reinforces nebivolol as an optimal therapeutic choice for managing hypertension across diverse patient groups.
Background /Objective:
Inappropriate Sinus Tachycardia (IST) is characterised by an elevated resting heart rate in the absence of an identifiable cause. First-line management includes beta-blockers, however, Ivabradine has emerged as a potential alternative that may offer better symptom control with fewer side effec...
Faizan Ahmed, F. Haider, M. Siddiqui et al.· Circulation· 0 citations
Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...
G. Marino, S. D. Di Fusco, E. Graziano et al.· Journal of Clinical Medicine· 0 citations
Background:
Hypertension remains a major therapeutic challenge with significant morbidity, requiring novel pharmacological options. Selective aldosterone synthase inhibitors (ASIs), particularly baxdrostat and lorundrostat, offer a potent approach to blood pressure control. However, their comparative renal safety pr...
Hamza Sajid, Hamdia Gul Aslam, Sarah Zaka et al.· Circulation· 0 citations
A meta-analysis of five RCTs shows baxdrostat significantly reduces SBP and DBP in resistant hypertension via selective aldosterone synthase inhibition, sparing cortisol, supporting its role as a promising novel therapeutic option.
Macitentan-containing therapy was associated with favorable changes in selected hemodynamic outcomes but not with a statistically significant improvement in 6MWD or mPAP, and the safety findings were characterized by higher risks of anemia, peripheral edema, and treatment discontinuation.
S. Gurram, V. Mp, S. Avula et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.